Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

http://www.wikidata.org/entity/Q34498728

about

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer.Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis

P2860

Q36700258-83492F06-315C-40C7-AC38-C5DF7B2C4661 Q38101884-57C44501-2E46-4151-B2A8-578AEBF8D8D9 Q38101885-75B968D9-0221-478F-AB37-6D2A44463155 Q39031326-2046736D-E4BF-4A78-AD7E-0C2016CB32CD Q39179464-8BE74ACE-99A9-49F1-97E6-B5458BC0272D Q42178081-98BFD413-D6B7-4006-8DFD-A733100FE7EF Q54114243-0D5A1D62-81BA-4DC6-8B30-8D32B60C6CBB Q54115504-9EED753E-C740-4EE3-9A10-629A23A53284 Q54339322-08ED589B-CEAF-4992-BCBF-CF2975D3F28F Q58803156-434038CE-DCBF-45B8-965A-CE828FB82F51

P2860

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

http://www.wikidata.org/entity/Q34498728

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@ast

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@en

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@nl

type

label

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@ast

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@en

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@nl

prefLabel

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@ast

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@en

Reduced CYP2D6 function is ass ...... th non-small cell lung cancer.

@nl

P1433

Q34498728-ED3FBDC1-66E8-4F20-BB15-414501A455C1

P1476

Q34498728-343238FF-EFBC-4F5A-8B56-588B59AE3DE8

P2093

Q34498728-17716ED1-332C-4735-A091-031C8B9649B9

Q34498728-2F8B902C-902F-45BA-9441-B87AF966C798

Q34498728-46EF60AC-6159-4ECC-A66C-4A2EFA54D15D

Q34498728-65B1E587-09F2-4B21-95CA-223475644EA6

Q34498728-79F5D0FC-BD2D-460B-905D-6D0EB81C327C

Q34498728-91F99B80-5C12-4AD6-ADE8-79A57E894191

Q34498728-95300909-7A87-4B36-8D93-402C8082FE95

Q34498728-9D3C794C-2251-40C1-AF30-608256F7C89B

Q34498728-BB2F12B2-5CFD-4ED9-838C-2FEA14D0E569

Q34498728-E4049E40-02D2-4BF4-8E11-F94EEFA95F64

P2860

Q34498728-00559E58-1BCA-44ED-B3B3-05A3CC90F5DE

Q34498728-0EFA86C2-423E-459E-AC5F-300D613D8F71

Q34498728-1018D989-0047-44D5-AF87-7A29EFA08E46

Q34498728-1330BF95-B0CC-4BE4-A57B-D37FBB764D2B

Q34498728-14BD3E03-7264-4552-B27F-051392F2EAC6

Q34498728-2A8C8F03-6581-431A-9ECA-53020298D0FA

Q34498728-2C57F6BD-8205-4A8E-A39A-D5A686342109

Q34498728-313D5727-837A-4247-BA6D-1151FFAA07CE

Q34498728-472C656F-92AD-4ADA-9A48-108E508D1BAD

Q34498728-4AD9DD0F-18FC-4B0A-BEC2-DA6047DAB7E2

P2888

Q34498728-7AAC18AD-C60E-4191-B657-69A201A9F6F1

P304

Q34498728-0D54491B-9867-4DA2-AC9C-527CC4B85C94

P31

Q34498728-65E996BF-B586-4FDE-BEFA-9C29312E1672

P356

Q34498728-4798A107-A60A-4ABD-9265-6D91E0433023

P407

Q34498728-C5529B23-82D1-4510-9267-D3EF0A566846

P478

Q34498728-F5982D74-7C31-4374-BF59-F24C414408CB

P50

Q34498728-C09F1C80-F8BE-4876-BDBF-BBC38B593FB8

P577

Q34498728-8C3F1741-97C1-431D-9284-C03AA84B31CB

P5875

Q34498728-AF965E48-9657-4E81-A4E1-0DF82542507F

P6179

Q34498728-A2718C26-89E3-4EA0-BDA5-D631F575D7BC

P698

Q34498728-9D9E4F4D-5C5C-43AC-92CB-017518ED607B

P932

Q34498728-EECC95F7-49AE-401C-B9E4-3E2389F8BC7E

P356

1471-2407-12-568

P1433

P1476

Reduced CYP2D6 function is ass ...... ith non-small cell lung cancer

@en

P2093

Hidenori Tanaka

http://www.w3.org/2001/XMLSchema#string

Kanako Umekawa

http://www.w3.org/2001/XMLSchema#string

Kazuto Hirata

http://www.w3.org/2001/XMLSchema#string

Kuniomi Matsuura

http://www.w3.org/2001/XMLSchema#string

Misato Nagata

http://www.w3.org/2001/XMLSchema#string

Naruo Yoshimura

http://www.w3.org/2001/XMLSchema#string

Shigeki Mitsuoka

http://www.w3.org/2001/XMLSchema#string

Shinzoh Kudoh

http://www.w3.org/2001/XMLSchema#string

Tatsuo Kimura

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Nakai

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

P2888

1471-2407-12-568

P304

568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-568

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Tomohiro Suzumura

P577

2012-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233838184

http://www.w3.org/2001/XMLSchema#string

P6179

1025739516

http://www.w3.org/2001/XMLSchema#string

P698

23207012

http://www.w3.org/2001/XMLSchema#string

P932

3536666

http://www.w3.org/2001/XMLSchema#string